Prevalence of human papillomavirus in oropharyngeal cancer

Cancer Journal (United States)

Volumn 21, Issue 3, 2015, Pages 138-146

  Stein, Andrew P ^a,b   Saha, Sandeep ^c   Kraninger, Jennifer L ^a   Swick, Adam D ^a   Yu, Menggang ^c   Lambert, Paul F ^b   Kimple, Randall J ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

HPV; human papillomavirus; OPSCC; oropharyngeal cancer; oropharyngeal squamous cell carcinoma

Indexed keywords

ARTICLE; CONFOUNDING VARIABLE; EUROPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; NORTH AMERICA; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CANCER; OROPHARYNX CARCINOMA; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; WART VIRUS; CARCINOMA, SQUAMOUS CELL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; PROGNOSIS; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS;

EID: 84930581467     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000115     Document Type: Article

References (52)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612-619.
3. Forte T, Niu J, Lockwood GA, et al. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control. 2012;23:1343-1348.
4. Braakhuis BJ, Visser O, Leemans CR. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol. 2009;45:e85-e89.
5. Hammarstedt L, DahlstrandH, Lindquist D, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 2007;127:988-992.
6. Reddy VM, Cundall-Curry D, BridgerMW. Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl. 2010;92:655-659.
7. Hocking JS, Stein A, Conway EL, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPVassociated oropharyngeal cancers. Br J Cancer. 2011;104:886-891.
8. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J ClinOncol. 2013;31:4550-4559.
9. IARCWorkingGroup on the Evaluation of Carcinogenic Risks to Humans: human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007; 90:637.
10. Rietbergen MM, Leemans CR, Bloemena E, et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer. 2013; 132:1565-1571.
11. Hong AM, Grulich AE, Jones D, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine. 2010;28:3269-3272.
12. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294-4301.
13. Nichols AC, Palma DA, Dhaliwal SS, et al. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Curr Oncol. 2013;20:212-219.
14. Avnstorp MB, Jensen RG, Garnaes E, et al. Human papillomavirus and oropharyngeal cancer in Greenland in 1994-2010. Int J Circumpolar Health. 2013;72:22386.
15. Schache AG, Liloglou T, Risk JM, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res. 2011; 17:6262-6271.
16. Hannisdal K, Schjolberg A, De Angelis PM, et al. Human papillomavirus (HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol. 2010;130:293-299.
17. Rodrigo JP, Heideman DA, Garcia-Pedrero JM, et al. Time trends in the prevalence of HPVin oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). Int J Cancer. 2014;134:487-492.
18. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma Int J Cancer. 2009;125:362-366.
19. Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1319-1331.
20. MehannaH, BeechT, NicholsonT, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic reviewand meta-analysis of trends by time and region. Head Neck. 2013;35:747-755.
21. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
22. Panwar A, Batra R, Lydiatt WM, et al. Human papilloma virus positive oropharyngeal squamous cell carcinoma: a growing epidemic. Cancer Treat Rev. 2014;40:215-219.
23. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.
24. Stein AP, Saha S, Yu M, et al. Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol. 2014;27:462-469.
25. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-475.
26. Nasman A, NordforsC, Holzhauser S, et al. Incidence of human papillomavirus positive tonsillar and base of tongue carcinoma: a stabilisation of an epidemic of viral induced carcinoma Eur J Cancer. 2015;51:55-61.
27. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420.
28. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956.
29. Newcomer SF, Udry JR. Oral sex in an adolescent population. Arch Sex Behav. 1985;14:41-46.
30. Billy JO, Tanfer K, Grady WR, et al. The sexual behavior of men in the United States. Fam Plann Perspect. 1993;25:52-60.
31. D'Souza G, Cullen K, Bowie J, et al. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One. 2014;9:e86023.
32. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307:693-703.
33. Centers for Disease C, Prevention. Cigarette smoking among adults-United States, 2006.MMWR Morb MortalWkly Rep. 2007;56:1157-1161.
34. Corsi DJ, Boyle MH, Lear SA, et al. Trends in smoking in Canada from 1950 to 2011: progression of the tobacco epidemic according to socioeconomic status and geography. Cancer Causes Control. 2014;25:45-57.
35. Centers for Disease C, Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:685-693.
36. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
37. Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
38. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8:e68329.
39. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine. 2012;30(Suppl 5): F139-F148.
40. Australian Government Department of Health. Immunise Australia Program. 2014. Last accessed March 1, 2014. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/resources-menu.
41. Public Health Agency of Canada. Update on human papillomavirus (HPV) vaccines. 2012. Last accessed March 1, 2014. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/assets/pdf/12vol-38-acs-dcc-1-eng.pdf.
42. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705-1708.
43. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117-1123.
44. Dok R, Kalev P, van Limbergen EJ, et al. p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Cancer Res. 2014;74:1739-1751.
45. Hoffmann M, Ihloff AS, Gorogh T, et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer. 2010;127:1595-1602.
46. El-Naggar AK, WestraWH. p16 expression as a surrogatemarker for HPVrelated oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012;34:459-461.
47. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284.
48. McLaughlin-Drubin ME, Park D, Munger K. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci USA. 2013;110:16175-16180.
49. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010;116:2166-2173.
50. Jordan RC, LingenMW, Perez-Ordonez B, et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol. 2012;36:945-954.
51. Ukpo OC, Flanagan JJ, Ma XJ, et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011;35:1343-1350.
52. Schache AG, Liloglou T, Risk JM, et al. Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br J Cancer. 2013;108:1332-1339.